Irritable Bowel Syndrome News

Personal genetics testing company 23andMe announced that a new collaboration with Pfizer will include genetic testing and analysis of 5,000 patients with systemic lupus erythematosus. The longitudinal study will integrate genetic data with medical records and will include targeted bio-sampling.

Mesalazine was not superior to placebo for treating symptoms of irritable bowel syndrome, according to new research data.

Diets that differed in fermentable oligosaccharides, disaccharides, monosaccharides and polyols, or FODMAP content, were shown to impact the composition of the gut microbiome, with significant differences noted, according to researchers.”

Traditional dietary advice for irritable bowel syndrome had comparable efficacy to a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols — or FODMAP — in improving gastrointestinal symptoms, according to data presented at UEG Week.

PHILADELPHIA — Volatile organic compounds were accurate in diagnosing irritable bowel syndrome among pediatric patients, according to data presented at the ACG Annual Scientific Meeting.

PHILADELPHIA — Plecanatide showed improvements in complete spontaneous bowel movements, abdominal pain and straining in a majority of patients with irritable bowel syndrome with constipation, according to a presenter at the ACG Annual Scientific Meeting. 

In a recent study, fear of gastrointestinal symptoms was found to be a strong predictor of impaired quality of life in patients with irritable bowel syndrome.

Patients with constipation-predominant irritable bowel syndrome treated with tenapanor experienced improved symptoms compared with patients who received placebo in a phase 2b clinical trial, according to a press release.

Recently the American College of Gastroenterology published new recommendations for the management of irritable bowel syndrome and chronic idiopathic constipation. Last updated in 2009, these guidelines incorporate data from numerous new studies. Here are 10 highlights of IBS research recently presented on Healio.com/Gastroenterology.

Salix Pharmaceuticals submitted its response to the FDA complete response letter concerning its supplemental new drug application for rifaximin, which proposed that the drug be indicated for diarrhea-predominant irritable bowel syndrome, according to a company press release.